Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway

Authors

Zifan Zhou, IQVIA
Robert Urman, Amgen Inc.
Karminder Gill, Amgen Inc.
Andrew S Park, Amgen Inc.
Fiston Vuvu, Amgen Inc.
Leah B Patel, Amgen Inc.
Jingsong Lu, IQVIA
Rolin L Wade, IQVIA
Lindsay Frerichs, Washington University School of Medicine in St. Louis
Mark E Bensink, Benofit Consulting

Journal

Journal of Headache and Pain

Publication Date

11-9-2023

Volume

24

Issue

1

First Page

153

Document Type

Open Access Publication

DOI

10.1186/s10194-023-01678-y

Rights and Permissions

Zhou, Z., Urman, R., Gill, K. et al. Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway. J Headache Pain 24, 153 (2023). https://doi.org/10.1186/s10194-023-01678-y This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Recommended Citation

Zhou, Zifan; Urman, Robert; Gill, Karminder; Park, Andrew S; Vuvu, Fiston; Patel, Leah B; Lu, Jingsong; Wade, Rolin L; Frerichs, Lindsay; and Bensink, Mark E, "Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway." Journal of Headache and Pain. 24, 1. 153 (2023).
https://digitalcommons.wustl.edu/oa_4/3376

Additional Links

Supplemental material is available for this article at publisher site.